OR WAIT null SECS
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
March 17, 2023
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
March 15, 2023
Manual aseptic operations make quality practices necessary in the manufacturing of compounded drugs.
March 09, 2023
Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.
Webinar Date/Time: Tuesday, April 4th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
March 08, 2023
Actylis new 30,000-ft² API manufacturing facility is located in Eugene, Ore.
Webinar Date/Time: Thu, Apr 6, 2023 11:00 AM EDT
March 03, 2023
PAT is crucial to process control and real-time release in continuous manufacturing of solid-dosage drugs.
March 02, 2023
Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.
Stockpiling excess inventory is no longer enough to respond to supply chain volatility.